• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Skye Bioscience Inc.

    11/15/24 5:28:24 PM ET
    $SKYE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SKYE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001425052
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Skye Bioscience, Inc.
    SEC File Number
    001-42009
    Address of Issuer
    11250 EL CAMINO REAL, SUITE 100
    SAN DIEGO
    CALIFORNIA
    92130
    Phone
    (858) 410-0266
    Name of Person for Whose Account the Securities are To Be Sold
    DHILLON PUNIT
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Piper Sandler & Co Inc
    800 Nicollet Mall
    Minneapolis � MN � 55402
    100693554818.433033829011/15/2024
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock11/15/2024CompensationIssuerCheckbox not checked10069311/15/2024NA

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/15/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Alex Johnson, a duly authorized representative of Piper Sandler & Co Corporate & Venture Services FA, as attorney-in-fact for Punit Dhillon

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SKYE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SKYE

    DatePrice TargetRatingAnalyst
    2/28/2025Outperform
    William Blair
    9/30/2024$20.00Sector Outperform
    Scotiabank
    9/10/2024$15.00Mkt Outperform
    JMP Securities
    7/9/2024$18.00Buy
    Craig Hallum
    5/23/2024$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SKYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Twitty Christopher claimed ownership of 81,242 shares (SEC Form 3)

      3 - Skye Bioscience, Inc. (0001516551) (Issuer)

      4/25/25 4:03:41 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: Chief Financial Officer Arsenault Kaitlyn sold $215,754 worth of shares (43,216 units at $4.99), decreasing direct ownership by 21% to 167,522 units (SEC Form 4)

      4/A - Skye Bioscience, Inc. (0001516551) (Issuer)

      2/28/25 6:54:45 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schwab Andrew J.

      4 - Skye Bioscience, Inc. (0001516551) (Issuer)

      2/26/25 7:45:56 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

      SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

      11/14/24 10:02:54 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Skye Bioscience Inc.

      SC 13G/A - Skye Bioscience, Inc. (0001516551) (Subject)

      11/14/24 9:21:21 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Skye Bioscience Inc.

      SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)

      8/14/24 4:59:17 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

      SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation development collaboration with Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives. The partnership aims to develop a higher concentration formulation of Skye's CB1 inhibitor, nimacimab, using Arecor's proprietary formulation technology platform, Arestat™. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase 2a CBeyond™ clinical

      5/19/25 5:00:49 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on May 7, 2025, the Board of Directors granted a non-qualified stock option award to purchase 100,000 shares of its common stock to one new non-executive employee under the Company's Amended and Restated 2024 Inducement Equity Incentive Plan (the "2024 Inducement Plan"). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively

      5/13/25 4:05:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

      • This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small molecule-based CB1 inhibitors, which both exhibited increasing dose-dependent brain penetration • This model predicts nimacimab's potentially superior therapeutic index, which is dependent on minimal brain exposure while maintaining sufficient peripheral inhibition SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic he

      5/13/25 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    SEC Filings

    See more
    • Skye Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Skye Bioscience, Inc. (0001516551) (Filer)

      5/8/25 4:05:16 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Skye Bioscience Inc.

      10-Q - Skye Bioscience, Inc. (0001516551) (Filer)

      5/8/25 4:03:41 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Skye Bioscience Inc.

      DEFA14A - Skye Bioscience, Inc. (0001516551) (Filer)

      4/25/25 4:01:21 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SKYE
    Leadership Updates

    Live Leadership Updates

    See more
    • William Blair initiated coverage on Skye Bioscience

      William Blair initiated coverage of Skye Bioscience with a rating of Outperform

      2/28/25 7:31:27 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Skye Bioscience with a new price target

      Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00

      9/30/24 7:51:18 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities initiated coverage on Skye Bioscience with a new price target

      JMP Securities initiated coverage of Skye Bioscience with a rating of Mkt Outperform and set a new price target of $15.00

      9/10/24 7:59:52 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

      SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer (CMO). "We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond™ obesity clinical trial for nimacimab, our differentiated CB1 inhibitor," said Punit Dhillon, Skye's CEO and Chair. "Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing cli

      9/3/24 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

      SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate achievements. "Our strategic acquisition of nimacimab in August 2023 has propelled Skye into the metabolic landscape, where there is a need to provide patients with obesity more tolerable and sustainable therapeutic alternatives to manage weight loss and address comorbid conditions," said Punit Dhillon, CEO of Skye. "In Q2, at our event, ‘Metabolic Rewiring wi

      8/9/24 5:59:37 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Appoints Dr. Karen Smith to Board of Directors

      SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company's operational and clinical expertise. Our strategic focus on the Nimacimab metabolic program will be supported by an evolving board as Keith Ward, PhD, and Praveen Tyle, PhD, resign from their roles as Boa

      7/3/24 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SKYE
    Financials

    Live finance-specific insights

    See more
    • Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

      Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data readout from CBeyond™ Phase 2a study of nimacimab expected late Q3/early Q4 2025 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage b

      5/8/25 4:01:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the c

      5/7/25 7:00:00 AM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removedPhase 2a dosing extended to 52 weeks to enhance long-term safety, tolerability, and efficacy dataCash runway projected through at least Q1 2027 SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye" or the "Company"), a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial resu

      3/20/25 4:01:00 PM ET
      $SKYE
      Biotechnology: Pharmaceutical Preparations
      Health Care